ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Ultrasound common hepatic artery denervation (CHA-D) as a novel neuromodulatory strategy for cardiovascular-kidney-metabolic syndrome: first-in-human experience.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHypertension may remain uncontrolled despite lifestyle measures, guideline-directed multidrug therapy, and renal denervation (RDN). Sympathetic overactivity contributes to persistent blood pressure (BP) elevation and cardiometabolic dysfunction. Given its central role in metabolic regulation and dense sympathetic innervation, the liver represents an attractive target for interventional neuromodulation.
methodsThis first-in-human ultrasound common hepatic artery denervation (CHA-D) was performed in a patient with recurrent uncontrolled hypertension and cardiometabolic comorbidity despite prior RDN and limited medical treatment options. Follow-up included ambulatory and office BP monitoring at 1 and 6 months, proton density fat fraction magnetic resonance imaging, metabolic parameters, and patient-reported outcomes (SF-36, EQ-5D-5L). In addition, current clinical studies evaluating CHA-D and multi-organ denervation were reviewed.
resultsThe procedure was completed successfully without intraprocedural complications. No hepatobiliary, pancreatic, or renal safety signal emerged during follow-up. Mean 24-h BP decreased from 179/88 mmHg at baseline to 151/87 mmHg at 1 month and 139/83 mmHg at 6 months, corresponding to systolic BP reductions of 28 and 40 mmHg, respectively, without intensification of antihypertensive therapy. Office BP decreased from 176/116 mmHg at baseline to 125/85 mmHg at 6 months. Hepatic fat fraction declined from 16.2% to 11.5%, HbA1c from 6.2% to 5.9%, insulin requirement was reduced, and body weight decreased by 8 kg. Patient-reported outcomes also improved during follow-up.
conclusionThis first-in-human experience suggests CHA-D as a technically feasible and safe neuromodulatory approach with convergent signals of hemodynamic and cardiometabolic benefit, supporting further prospective evaluation of CHA-D in cardiovascular-kidney-metabolic syndrome.
Indexed as
Identifiers
42234130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.